| Literature DB >> 28646223 |
Ivan Dimauro1, Antonella Sgura2, Monica Pittaluga1, Fiorenza Magi1, Cristina Fantini1, Rosa Mancinelli3, Antonio Sgadari4, Stefania Fulle3, Daniela Caporossi5.
Abstract
Physical activity has been demonstrated to be effective in the prevention and treatment of different chronic conditions, including type 2 diabetes (T2D). In particular, several studies highlighted how the beneficial effects of physical activity may be related to the stability of the DNA molecule, such as longer telomeric ends. Here we analyze the effect of exercise training on telomere length, spontaneous and H2O2-induced DNA damage, as well as the apoptosis level in leukocytes from untrained or trained T2D patients vs. age-matched control subjects (CS) (57-66 years). Moreover, expression analysis of selected genes belonging to DNA repair systems, cell cycle control, antioxidant and defence systems was performed. Subjects that participated in a regular exercise program showed a longer telomere sequence than untrained counterparts. Moreover, ex vivo treatment of leukocytes with H2O2 highlighted that: (1) oxidative DNA damage induced similar telomere attrition in all groups; (2) in T2D subjects, physical activity seemed to prevent a significant increase of genomic oxidative DNA damage induced by chronic exposure to pro-oxidant stimulus, and (3) decreased the sensitivity of leukocytes to apoptosis. Finally, the gene expression analysis in T2D subjects suggested an adaptive response to prolonged exercise training that improved the response of specific genes.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28646223 PMCID: PMC5482873 DOI: 10.1038/s41598-017-04448-4
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Subject characteristics.
| T2D | CS | |||
|---|---|---|---|---|
| UT ( | TR ( | UT ( | TR ( | |
| AGE (yrs) | 61.1 ± 3.3 | 60.1 ± 2.1 | 62.1 ± 1.3 | 62.1 ± 4.3 |
| BMI (kg/m2) | 27.9 ± 2.0 | 26.9 ± 1.6** | 27.8 ± 2.0 | 27.1 ± 1.3 |
| BG (mg/dL) | 116.3 ± 12.5 | 106.4 ± 6.1* | 87.8 ± 8.4 | 90.3 ± 10.2 |
| HbA1c (%) | 6.7 ± 0.7 | 6.3 ± 0.5* | 5.5 ± 0.2 | 5.4 ± 0.3 |
| Duration of T2D (yrs) | 6.2 ± 0.8 | 6.3 ± 1.2 | — | — |
BMI, Body Mass Index; BG, Basal Glycaemia; HbA1c, Glycated Haemoglobin; T2D, Type 2 diabetes; CS, control subjects; UT, untrained; TR, trained. **p < 0.01 vs. UT, *p < 0.05 vs. UT. All values are shown as means ± SD.
Figure 1Comparison of leukocytes telomere length in study participants: control subjects (CS) and diabetic patients (T2D) when untrained (UT) and trained (TR) respectively. *p < 0.05 vs. UT-CS, §§p < 0.01 vs. UT-T2D, §p < 0.05 vs. UT-T2D.
Figure 2Leukocytes DNA damage in control subjects (CS) and diabetic patients (T2D) of untrained (UT) and trained (TR) groups.
Figure 3Fold change decrease of telomere length relative to untreated cells in leukocytes of untrained and trained controls (UT-CS: H2O2(0.5h) 0.86 ± 0.08; H2O2(48h) 0.76 ± 0.1; H2O2(72h) 0.78 ± 0.06; TR-CS: H2O2(0.5h) 0.81 ± 0.13; H2O2(48h) 0.70 ± 0.09; H2O2(72h) 0.77 ± 0.09) (3A) or untrained and trained diabetic patients (UT-T2D: H2O2(0.5h) 0.81 ± 0.09; H2O2(48h) 0.72 ± 0.08; H2O2(72h) 0.78 ± 0.07; TR-T2D: H2O2(0.5h) 0.74 ± 0.07; H2O2(48h) 0.68 ± 0.19; H2O2(72h), 0.73 ± 0.15) (3B). **p < 0.01 and *p < 0.05 vs. corresponding untreated cells. Dashed horizontal line represents no change in telomere length.
Figure 4DNA damage analysis in leukocytes of (A) control (CS) untrained (UT) and trained (TR), and (B) diabetic patients (T2D) UT and TR, following an acute (100 μM for 0.5 hrs) or a chronic (30 μM for 72 h) treatment with H2O2. **p < 0.01.
Figure 5Apoptosis analysis in leukocytes of diabetic patients (T2D) trained (TR) and untrained (UT) following an acute (100 μM for 0.5 hrs) or chronic (30 μM for 72 h) treatment with H2O2. Apoptosis percentage was evaluated by scoring the number of TUNEL positive nuclei on at least 1000 cells analyzed ×100. **p < 0.01.
Gene expression analysis in human leukocytes.
| Cellular Pathway | Gene | T2D TR |
|---|---|---|
| Base Excision Repair | APEX1 |
|
| FEN1 |
| |
| LIG1 |
| |
| LIG3 |
| |
| MPG |
| |
| OGG1 |
| |
| PARP1 |
| |
| PCNA |
| |
| PNKP |
| |
| POLB |
| |
| TDG |
| |
| UNG |
| |
| CCNO |
| |
| XRCC1 |
| |
| Damaged DNA Binding | BRCA1 |
|
| ERCC1 |
| |
| ERCC2 |
| |
| H2AFX |
| |
| MSH2 |
| |
| MSH3 |
| |
| RAD1 |
| |
| RAD51 |
| |
| RAD51C |
| |
| XRCC2 |
| |
| XPA |
| |
| XPC |
| |
| MUTYH |
| |
| NTHL1 |
| |
| Double Strand Breaks Repair | BRCA2 |
|
| MRE11 |
| |
| PRKDC |
| |
| RAD52 |
| |
| XRCC6 |
| |
| Cell Cycle Checkpoints and Apoptosis | TP53 |
|
| ATM |
| |
| BAX |
| |
| BCL2 |
| |
| CASP3 |
| |
| CHECK1 |
| |
| GADD45 |
| |
| Antioxidants and Defence Systems | CAT |
|
| SOD1 |
| |
| GPX1 |
| |
| GSR |
| |
| OXR1 |
| |
| HSPA4 |
|
Calculated fold changes of 46 PCR gene products derived from RT-qPCR-array. *p < 0.05, **p < 0.01. T2D, Type 2 Diabetes; UT, untrained; TR, trained; N/A, not available.